Antibodies are produced by the immune system of an animal in a specific response to a challenge by an immunogen. The immune system acts through two principal mechanisms humoral type responses (production of antibodies) and cell-mediated responses. Immunogens (antigens) are molecules that can induce a specific immune response and are usually foreign proteins or carbohydrates, or sometimes lipids and nucleic acids. The immune systems of mammals are comprised of large numbers of lymphocytes, each characterized by its unique antigen-receptor specificity. This receptor diversity permits immune responses to a broad range of immunogens these factors are driving the market growth.
The overall Global Antibody Production Market was valued at $8.8bn in 2018 and is forecasted to grow at a CAGR of 12.29% between 2018 and 2026, resulting in 2026 global sales of $ 23.22 bn. However, Strict government regulations are restraining the market growth. Moreover, increasing acceptance of targeted therapy is provided ample opportunities for the market.
Antibody Production depending on Type, Monoclonal antibody segment is expected to account for the largest share of the Antibody Production market due to Monoclonal antibodies (mAb) are used extensively in basic biomedical research, in the diagnosis of disease, and in treatment of illnesses, such as infections and cancer.
The Global Antibody Production Market is segmented on the basis of Process, Type, End-User and Region
Based on the Process: Filtration, Multimodal Chromatography Resins, Hydrophobic Interaction, Chromatography (HIC) Resins, Ion Exchange (IEX) Chromatography Resins, Downstream Processing, and Upstream Processing
Based on the Type: Monoclonal antibody and Polyclonal antibody
Based on the End-User: Research laboratories, Pharmaceutical, and biotechnology companies and Other End Users
Report Description: The report covers in-depth analysis of the Global Antibody Production Market. The report assesses the market products pipeline by stage of development (early development, pre-clinical, clinical and in approval), by type (Monoclonal antibody and Polyclonal antibody). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.
The report includes in-depth company profiles of key players in the Global Antibody Production Market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary databases and Models)
Market-related information is assembled from both primary and secondary sources.
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.